Phillip Digiacomo is a Vice President at Qiming Venture Partners US and a Board Observer at Abdera Therapeutics. He joined Qiming US in 2020 after completing his Ph.D. in Bioengineering from Stanford University. Prior to that, he worked as an associate at ND Capital, where he focused on sourcing and diligence of early-stage life science companies, as well as portfolio support. His research at Stanford University focused on the discovery and development of novel biomarkers and therapeutic targets for neuroinflammatory diseases.